Pharmaceutical company GSK has paid $70 million to partner with precision medicine company Tempus.
Through the partnership, GSK will have access to Tempus' artificial intelligence platform and portfolio of deidentified patient data. The partnership aims to speed up enrollment, improve the clinical design and identify drug targets, according to an Oct. 18 GSK news release.
The collaboration will take place over three years.
"GSK's data-first approach to therapeutic research aligns with our own, and we believe that Tempus has the resources and capabilities to complement GSK's dedication to data science in a way others can't given the breadth and depth of our platform," Tempus founder and CEO Eric Lefkofsky said. "We both share a commitment to providing patients with more personalized therapeutic options to help them live longer and healthier lives."